Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 675 of 3499 entries
View as:

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04959175 Org: User:
Start: 09/23/21 End: 04/30/27 Due: 04/30/28

Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01132573 Org: User:
Start: 04/30/10 End: - Due: -

Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia

Phase: N/A Priority: Normal
NCT ID: NCT00335504 Org: User:
Start: 03/31/06 End: 04/30/09 Due: 04/30/10

Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01281852 Org: User:
Start: 03/14/11 End: 02/11/17 Due: 02/11/18

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00471536 Org: User:
Start: 08/31/08 End: 12/31/13 Due: 12/31/14

Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00114283 Org: User:
Start: 03/31/05 End: 10/31/06 Due: 10/31/07

Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor

Phase: N/A Priority: Normal
NCT ID: NCT00028002 Org: User:
Start: 03/31/02 End: 01/28/09 Due: 01/28/10

Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients

Phase: N/A Priority: Normal
NCT ID: NCT01402284 Org: User:
Start: 07/21/11 End: 09/24/20 Due: 09/24/21

RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01251172 Org: User:
Start: 12/31/10 End: - Due: -

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

Phase: N/A Priority: Normal
NCT ID: NCT01767194 Org: User:
Start: 02/12/13 End: 09/30/22 Due: 09/30/23

Interdisciplinary Case-Control Study of Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00341952 Org: User:
Start: 04/15/98 End: 04/17/07 Due: 04/17/08

Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)

Phase: N/A Priority: Normal
NCT ID: NCT02179515 Org: User:
Start: 06/28/14 End: 02/28/18 Due: 02/28/19

A Study of Familial and Genetic Aspects of Adult T-Cell: Leukemia/Lymphoma , Tropical Spastic Paraparesis, and Infective Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT00340821 Org: User:
Start: 05/17/93 End: 03/01/11 Due: 03/01/12

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01515176 Org: User:
Start: 01/31/12 End: 07/19/16 Due: 07/19/17

Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01199263 Org: User:
Start: 12/06/10 End: 07/17/20 Due: 07/17/21

Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01468909 Org: User:
Start: 12/12/11 End: 01/27/18 Due: 01/27/19

Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00066625 Org: User:
Start: 07/31/03 End: - Due: -

A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant

Phase: N/A Priority: Normal
NCT ID: NCT00001439 Org: User:
Start: 06/30/95 End: 04/30/00 Due: 04/30/01

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Phase: N/A Priority: Normal
NCT ID: NCT05554354 Org: User:
Start: 09/13/24 End: 04/04/25 Due: 04/04/26

Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists

Phase: N/A Priority: Normal
NCT ID: NCT02911155 Org: User:
Start: 09/21/16 End: 05/01/20 Due: 05/01/21

Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00020007 Org: User:
Start: 12/31/99 End: - Due: -

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02484430 Org: User:
Start: 04/06/17 End: 03/05/24 Due: 03/05/25

Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT00379080 Org: User:
Start: 01/31/07 End: 06/30/13 Due: 06/30/14

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00089063 Org: User:
Start: 06/30/04 End: 06/30/07 Due: 06/30/08

Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00729157 Org: User:
Start: 08/31/08 End: 11/30/12 Due: 11/30/13